Companies · Medical Devices

AI DiagnosticsNew on the radar

Cape Town · Africa · Medical Devices · founded 2020

Diligence memoA one-page analyst read on AI Diagnostics — recommendation, valuation, rhythm, risks.
$5.2M
Total raised · real
1
Rounds
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Fri Apr 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

AI Diagnostics looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the medical devices sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.23× the median modeled value of Series A Medical Devices companies in 2025–2027 (10 peers) — value vs value, same stage and era.
  • Within the normal band (123% of peer median) for its niche.
Active
  • Last raise 2 mo ago; this sector typically re-raises about every 16 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

3 Investors
Where it sits in Medical Devices

AI Diagnostics is one of 233 Medical Devices companies tracked from Cape Town, Africa, on record since 2020. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

SA med-tech company AI Diagnostics raises $5.2m to accelerate AI-powered TB screening 0 By Tom Jackson on April 17, 2026 News , Southern Africa South African med-tech company AI Diagnostics has raised ZAR85 million (US$5.2 million) in funding to advance the use of its proprietary hardware and AI software in combatting the tuberculosis (TB) epidemic. Founded in 2020, the Cape Town-based AI Diagnostics develops accessible, early screening tools that empower frontline healthcare workers.

SA med-tech company AI Diagnostics raises $5.2m to accelerate AI-powered TB screening 0 By Tom Jackson on April 17, 2026 News , Southern Africa South African med-tech company AI Diagnostics has raised ZAR85 million (US$5.2 million) in funding to advance the use of its proprietary hardware and AI software in combatting the tuberculosis (TB) epidemic. Founded in 2020, the Cape Town-based AI Diagnostics develops accessible, early screening tools that empower frontline healthcare workers.

ai/mlmedical-devices

As reported in public records reported — not modeled.

ZA
Jurisdiction
3
Investors (latest)
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MSeries A · 2026-04-17 Raised $5.2M (real) Modeled valuation $13M (est)$5.2M$13MSeries A2026

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.2M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$12.7M
Base estimate est.
$6.4M
Conservative case
$18.1M
Upside case
$23.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the medical devices sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
50%
Survival probability
27% low · 68% high
1.49×/yr
Annual markup
1.87×/yr upside case
0.2 yr
Elapsed time used
0.2 yr actual, capped for stale marks
medical devices
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
0.2 yr
On record since
2026
First round
New
First-time filer
How it compares to the market

Benchmarked against 233 companies in Medical Devices. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.0× above median
This company$5.2M
Sector median$2.6M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$5.2M
Sector median$4.6M
Modeled value — vs sector median (estimate, all stages) 0.8× of median
This company$12.7M
Sector median$15.4M

Raised more than 69% of sector peers (real $). Modeled value above 54% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 10.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Curadel Surgical Innovations, Inc. · Series A Raised $26.0M · modeled $44.1M (est)Gestalt Diagnostics, LLC · Series A Raised $9.6M · modeled $25.2M (est)ClearCut Surgical, Inc. · Series A Raised $4.5M · modeled $15.1M (est)Bayou Surgical, Inc. · Series A Raised $13.2M · modeled $14.8M (est)NexEos Diagnostics, Inc. · Series A Raised $25.7M · modeled $7.9M (est)ReadySet Surgical, Inc. · Series A Raised $9.9M · modeled $7.6M (est)Black Light Surgical, Inc. · Series A Raised $12.9M · modeled $6.9M (est)EDGe Surgical, Inc. · Series A Raised $10.2M · modeled $3.6M (est)Surgical Center of Greensboro, LLC · Series A Raised $12.4M · modeled $2.9M (est)AI Diagnostics (this company) Raised $5.2M · modeled $12.7M (est)AI Diagnostics
CompanyStageRaised · realValue · estvs peer med.
Curadel Surgical Innovations, Inc.Series A$26.0M$44.1M4.27×
Gestalt Diagnostics, LLCSeries A$9.6M$25.2M2.44×
ClearCut Surgical, Inc.Series A$4.5M$15.1M1.47×
Bayou Surgical, Inc.Series A$13.2M$14.8M1.43×
AI Diagnostics this companySeries A$5.2M$12.7M1.23×
NexEos Diagnostics, Inc.Series A$25.7M$7.9M0.77×
ReadySet Surgical, Inc.Series A$9.9M$7.6M0.74×
Black Light Surgical, Inc.Series A$12.9M$6.9M0.66×
EDGe Surgical, Inc.Series A$10.2M$3.6M0.35×
Surgical Center of Greensboro, LLCSeries A$12.4M$2.9M0.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.2M2026-04-17$23.6M$12.7M45%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.2M2026-04-17
    • First recorded raise — entered as Series A.
    • 3 investors on this round.
Intelligence
Modeled next raise
$8.3M
Modeled next size est.range $5.4M$13.3M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

AI Diagnostics is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
ZA
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CAIRA Surgical CorpMedical DevicesSeries A$5.2M$85.3Msame sector · same stage
Allotrope Medical Inc.Medical DevicesSeries A$5.0M$93.5Msame sector · same stage
Trilliant Surgical, LLCMedical DevicesSeries A$5.7M$17.4Msame sector · same stage
Thunder Road Surgical, LlcMedical DevicesSeries A$5.8M$62.7Msame sector · same stage
ClearCut Surgical, Inc.Medical DevicesSeries A$4.5M$15.1Msame sector · same stage
Hyperion Surgical, Inc.Medical DevicesSeries A$6.0M$38.7Msame sector · same stage
Acera Surgical, Inc.Medical DevicesSeries A$6.2M$123.6Msame sector · same stage
Juno Diagnostics, Inc.Medical DevicesSeries A$6.3M$107.8Msame sector · same stage
Investors

Public records name issuer insiders, not the funds in a round — these investor links come from corroborating sources.

FirmRoundConfidence
Africa Health VenturesSeries A55%
Global Innovation FundSeries A55%
Steele FoundationSeries A55%
Frequently asked
How much funding has AI Diagnostics raised?
AI Diagnostics has raised approximately $5.2M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is AI Diagnostics's estimated valuation?
Provath's modeled valuation for AI Diagnostics is approximately $12.7M (modeled range $6.4M–$18.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AI Diagnostics at?
AI Diagnostics's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Apr 17.
What does AI Diagnostics do and where is it based?
AI Diagnostics operates in the Medical Devices sector, based in Cape Town, Africa. SA med-tech company AI Diagnostics raises $5.2m to accelerate AI-powered TB screening 0 By Tom Jackson on April 17, 2026 News , Southern Africa South African med-tech company AI Diagnostics has raised ZAR85 million (US$5.2 million) in funding to advance the use of its proprietary hardware and AI software in combatting the tuberculosis (TB) epidemic. Founded in 2020, the Cape Town-based AI Diagnostics develops accessible, early screening tools that empower frontline healthcare workers.
Explore related

See where AI Diagnostics sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AI Diagnostics, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.